Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins
- 1 September 2010
- journal article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 49 (9) , 567-571
Abstract
Low-molecular-weight heparins are anticoagulants used in the treatment of thrombosis. They have effectiveness and safety profiles similar to those of unfractionated heparin but are considered an attractive alternative because of their predictable pharmacokinetic characteristics. In this article, we demonstrate the need for therapeutic monitoring of low-molecular-weight heparins by addressing evidence arising from the literature and from modelling and simulation. First, treatment targets for unfractionated heparin and enoxaparin sodium were identified. Then, 10 000 virtual patients were simulated and the rate of treatment success was calculated. Treatment success was found to be similar between the two drugs (48% with unfractionated heparin and 54% with enoxaparin sodium). These results are consistent with empirical evidence from the literature and reflect the inadequacy of current dosing strategies in achieving desired biomarker targets. These results, along with recent advances in Bayesian forecasting techniques, support the need for routine monitoring and dose individualization of enoxaparin sodium in order to improve treatment success.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysisEuropean Heart Journal, 2007
- Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromesBritish Journal of Clinical Pharmacology, 2005
- Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism2004
- Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With EnoxaparinCirculation, 2004
- Development of a dosing strategy for enoxaparin in obese patientsBritish Journal of Clinical Pharmacology, 2003
- Low molecular weight heparins versus unfractionated heparin for acute coronary syndromesCochrane Database of Systematic Reviews, 2003
- Successors to heparin: New antithrombotic agentsAmerican Heart Journal, 1997
- Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of TIMI 11A 11A list of the participating investigators and clinical centers for the TIMI 11A trial appears in the Appendix A.JACC, 1997
- Bayesian Forecasting of APTT Response to Continuously Infused Heparin with and Without Warfarin AdministrationThe Journal of Clinical Pharmacology, 1989
- Comparison of Drug Dosing MethodsClinical Pharmacokinetics, 1985